CytoDyn (OTCMKTS:CYDY – Get Free Report) released its earnings results on Wednesday. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.04, Zacks reports.
CytoDyn Price Performance
Shares of CYDY opened at $0.20 on Thursday. The company’s fifty day moving average price is $0.21 and its 200-day moving average price is $0.25. CytoDyn has a 1-year low of $0.18 and a 1-year high of $0.40. The firm has a market capitalization of $303.70 million, a PE ratio of -10.00 and a beta of 1.50.
CytoDyn Company Profile
CytoDyn Inc is a biotechnology company focused on the development of leronlimab, an investigational monoclonal antibody that targets CCR5, a receptor involved in immune-cell signaling and the movement of certain cells through the body. The company’s research has explored potential applications in infectious diseases, oncology and inflammatory conditions.
Leronlimab, also known as PRO 140, has been studied primarily as a potential treatment for HIV infection, including in combination with existing antiretroviral therapies.
See Also
- Five stocks we like better than CytoDyn
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
